Neuropathic pain is a debilitating condition that is often resistant to common analgesics, such as opioids, but is sensitive to some antidepressants, an effect that seems to be mediated by spinal cord 5-HT 3 receptors. Because the analgesic potential of monoamine oxidase-A (MAO-A) inhibitors is understudied, we evaluated the potential antinociceptive effect of the reversible MAO-A inhibitors moclobemide and 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in a mouse neuropathic pain model induced by chronic constriction injury (CCI) of the sciatic nerve. Neuropathic mice showed a decreased mechanical paw withdrawal threshold (PWT) 7 days after lesion compared with the baseline PWT, characterizing the development of hyperalgesia. Moclobemide (100-300 μmol/kg, s.c.) and 2-DMPI (30-300 μmol/kg, s.c.) treatments were able to reverse the CCI-induced hyperalgesia, with 50% inhibitory dose (ID 50 ) values of 39 (18-84) and 11 (4-33) μmol/kg, and maximum inhibition (I max ) values of 88 ± 14 and 98 ± 15%, respectively, at the 300 μmol/kg dose. In addition, we observed a significant increase in the MAO-A activity in the lumbar spinal cord of CCI-submitted mice compared with sham-operated animals. Furthermore, the antihyperalgesic effects of both 2-DMPI and moclobemide were largely reversed by intrathecal injection of the 5-HT 3 receptor antagonist ondansetron (10 μg/site). These results suggest a possible involvement of MAO-A in the mechanisms of neuropathic pain and a potential utility of the reversible inhibitors of MAO-A in the development of new therapeutic approaches to treat it.
Introduction
Neuropathic pain is a pathological condition that frequently results from a lesion or disease of the somatosensory nervous system (Treede et al., 2008) . Common complaints of neuropathic pain patients are spontaneous pain and painful hypersensitivity to mechanical, thermal and/or chemical noxious (hyperalgesia) or innocuous (allodynia) stimuli (Costigan et al., 2009 ). The management of neuropathic pain is still a major challenge to clinicians because it is unresponsive to most of the currently used analgesic drugs (Dworkin et al., 2007; Woolf and Mannion, 1999) . In this regard, some antidepressants represent useful tools in neuropathic pain treatment (Sindrup et al., 2005) . In fact, tricyclic antidepressants, together with anticonvulsants, are considered to be first-line drugs for the treatment of neuropathic pain (Micó et al., 2006) .
Although antidepressants have been used for the treatment of chronic pain conditions for decades, the mechanism of this action is still unclear. Many believe that the increased availability of serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline in the synaptic cleft is the main mechanism of the analgesic action of antidepressants (Micó et al., 2006) . Furthermore, 5-HT 3 receptor activation has been implicated in the antinociceptive effect of spinal serotonin by increasing the activity of the descending inhibitory pathways (Bardin et al., 2000) , which may be compromised in chronic pain conditions (Ardid et al., 1995) .
Similar to tricyclic antidepressants, monoamine oxidase (MAO) inhibitors also increase the availability of monoamines in the central nervous system (Youdim et al., 2006) . Although some authors have shown the analgesic properties of reversible MAO-A inhibitors, such as moclobemide, in the treatment of nociceptive and psychogenic pain (Coquoz et al., 1993; Pirildar et al., 2003; Schreiber et al., 1998) , there are only a few preliminary studies evaluating the therapeutic potential of these drugs for neuropathic pain and their results are controversial (Apaydin et al., 2001; Menkes et al., 1995) .
Because neuropathic pain is a debilitating condition of difficult treatment and antidepressants have long been used for the treatment of this type of pain (Sindrup et al., 2005) , the aims of this study were to confirm the antinociceptive potential of the reversible MAO-A inhibitor moclobemide and evaluate the effect of 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole (2-DPMI), a novel reversible and preferential MAO-A inhibitor with antidepressant properties (Villarinho et al., 2012a) , in a mouse neuropathic pain model. We also investigated possible changes in monoamine oxidase activity in neuropathic mice, as well as the involvement of spinal 5-HT 3 receptors in the antinociceptive effect of reversible MAO-A inhibitors.
Materials and methods

Animals
Experiments were conducted using male Swiss mice (25-30 g) from our own colony. Mice were maintained in polycarbonate cages with free access to food and water on a 12 h alternating light-dark schedule in a temperature-controlled (22 ± 3°C) room. Mice were kept and used in accordance with the guidelines of the National Council for Control of Animal Experiments (CONCEA) and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experiments pertaining to this study were approved by the Ethics Committee of the Federal University of Santa Maria (process number 64/2011). The number of animals and intensity of the noxious stimuli used were the minimum necessary to demonstrate the consistent effects of drug treatments. For behavioral tests, drugs were administered in a random order and the behavioral measure was carried out by a blinded investigator. Animals were allowed to adapt to the test environment for 2 h before testing.
Drugs
The synthesis of 2-DMPI was carried out by the previously reported method of condensation involving 3,4-dimethoxybenzaldehyde and ethylenediamine in the presence of N-bromosuccinimide under ultrasound irradiation (Sant'Anna et al., 2009) . Analysis of 1 H and 13 C nuclear magnetic resonance spectra showed analytical and spectroscopic data in full agreement with the assigned structure. Moclobemide (Aurorix®, Roche, Brazil) and 2-DMPI were dissolved in a vehicle solution (5% Tween 80, 20% polyethyleneglycol and 75% saline) and pregabalin (Lyrica®, Pfizer, Brazil) was dissolved in sterile saline. Moclobemide, 2-DMPI and pregabalin were administered to mice by the subcutaneous (s.c.) route, while ondansetron (Nausedron®, Cristália, Brazil) was intrathecally (i.t.) injected in a volume of 5 μL, according to the technique described by Hylden and Wilcox (1980) . Kynuramine dihydrobromide and selegiline hydrochloride were purchased from Sigma Chemical Co. (St. Louis, USA) and dissolved in incubation buffer. All other reagents were of analytical grade and were purchased from local suppliers.
Measurement of mechanical hyperalgesia
In this study, we used mechanical hyperalgesia as a parameter of nociception, which was characterized by a significant decrease in the mechanical paw withdrawal threshold (PWT). The measurement of mechanical PWT was carried out using the up-and-down paradigm as previously described by Chaplan et al. (1994) for rats and adapted by Villarinho et al. (2012b) for mice. Briefly, mice were first acclimatized in individual clear Plexiglas boxes (9×7×11 cm) on an elevated wire mesh platform to allow the access to the plantar surface of the right hind paw. Seven calibrated von Frey filaments of increasing stiffness (0.02, 0.07, 0.16, 0.4, 1.4, 4 , and 10 g) were chosen. Testing was initiated with the 0.4 g hair, and each hair was applied perpendicularly to the plantar surface of the right hind paw, with sufficient force to bend the filament, for about 5 s. Lifting of the paw indicated a positive response and prompted the use of the next weaker (i.e. lighter) filament. Absence of a paw withdrawal response prompted the use of the next stronger (i.e. heavier) filament. This paradigm continued until a total of six measurements or until four consecutive positive or four consecutive negative responses occurred. All measurements were carried out in the paw ipsilateral to the surgical or sham procedure, and the 50% mechanical PWT response was calculated from the resulting scores as previously described by Dixon (1980) . The 50% PWT was expressed in grams (g) and was evaluated before (baseline) and several times after treatments or surgical procedures.
Neuropathic pain model
For induction of chronic mononeuropathy, mice were first anesthetized by intraperitoneal injection of 90 mg/kg of ketamine plus 3 mg/kg of xylazine hydrochloride. Neuropathy was induced by chronic constriction injury (CCI) of the sciatic nerve using a similar procedure to that previously described by Bennett and Xie (1988) for rats and adapted by Sommer et al. (1998) for mice. Three loosely constrictive ligatures were placed around the right sciatic nerve under anesthesia. In sham surgeries, animals were anesthetized and the sciatic nerve was exposed without performing constriction. Sham-operated animals were used as controls.
Seven days after the procedures (sham or CCI), the nociception test was carried out at time 0 (before drug injection). Then, mice were treated with 2-DMPI (300 μmol/kg, s.c.), moclobemide (300 μmol/kg, s.c.), vehicle (10 mL/kg, s.c.), pregabalin (100 μmol/kg, s.c.), or saline (10 mL/kg, s.c.), and mechanical sensitivity was measured 1, 2, 4, 6, and 24 h after treatment (time-course curve). For the dose-response curve, CCI-submitted animals received a single injection of 2-DMPI (3, 30, or 300 μmol/kg, s.c.), moclobemide (30, 100, or 300 μmol/kg, s.c.), or vehicle 2 h before the nociceptive test. To assess the involvement of the serotonergic system in the antinociceptive effect of reversible MAO-A inhibitors, mice received an intrathecal injection of the 5-HT 3 receptor antagonist ondansetron (10 μg/site) or phosphate buffered saline (PBS; 5 μL/site), 30 min before the peak effect of the drugs (90 min after subcutaneous injection of 2-DMPI or moclobemide). The mechanical paw withdrawal threshold was measured 30 min later. The dose of ondansetron was selected based on the results of a previous study (Dogrul et al., 2012) .
Determination of MAO-A activity
For MAO-A activity measurement, mice submitted to surgical procedure (sham or CCI) were killed 7 days after the surgical procedure and different central nervous system structures (lumbar spinal cord, cerebral cortex, and striatum) were collected and homogenized in assay buffer (16.8 mM Na 2 HPO 4 , 10.6 mM KH 2 PO 4 , and 3.6 mM KCl, pH 7.4). The entire lumbar spinal cord (L1 to L6) was dissected by mechanical extrusion. The MAO-A activity was measured by a fluorometric method that detects the formation of the fluorescent product 4-hydroxyquinoline (4-HQ) from kynuramine, as previously described (Matsumoto et al., 1985; Villarinho et al., 2012b) . Briefly, assays were performed in a reaction mix containing assay buffer, tissue homogenates of central nervous system structures (0.25 mg of protein), the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (250 nM), and kynuramine (100 μM) and were incubated at 37°C for 30 min. The results were expressed as nmol of 4-HQ/ min/mg of protein.
Rota-rod test
Motor coordination was evaluated using the rota-rod test (Godoy et al., 2004) . The apparatus consisted of a bar (3.7 cm in diameter) divided into 3 separate compartments, placed at a 25 cm height and rotating at a fixed velocity of 8 rpm. Twenty-four hours before testing, all animals were submitted to a training session until they could remain in the apparatus for 60 s without falling. On the test day, mice received a single injection of moclobemide (300 μmol/kg, s.c., 2 h before test), 2-DMPI (300 μmol/kg, s.c., 2 h before test), vehicle (10 mL/kg, s.c., 2 h before test), pregabalin (100 μmol/kg, s.c., 1 h before test), or saline (10 mL/kg, s.c., 1 h before test). During the test session, the latency (in seconds) for the first fall and the total number of fall during a 4 min period were measured.
Statistical analyses
The results were expressed as the means ± S.E.M., except for the ID 50 values (i.e., the drug dose that reduces nociceptive responses by 50% relative to the control value), which were expressed as geometric means accompanied by their respective 95% confidence limits, and the latency for the first fall and the fall number (rota-rod test), which were represented as medians followed by their 25th and 75th percentiles. ID 50 values were determined by non-linear regression using a sigmoidal dose-response with a variable slope equation. The percentages of maximum inhibition (I max ) were calculated for the maximal developed responses in comparison with vehicle-treated animals. Statistical analyses were carried out using GraphPad Prism 5.0 software. Differences among groups were evaluated with an unpaired t-test, one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test, or two-way ANOVA followed by Bonferroni's test, as appropriate. Reported F values were obtained from two-way ANOVA analysis and indicate the interaction between time and treatment factors. Differences were considered significant when P b 0.05.
Results
Effects of reversible MAO-A inhibitors and pregabalin on CCI-induced hyperalgesia
Mechanical nociceptive thresholds were stable before and after the sham procedure in both vehicle and moclobemide (300 μmol/kg, s.c.)-treated mice ( Fig. 1A ; F(6,72) = 0.56, P = 0.763). On the other hand, CCI of the sciatic nerve decreased the mean PWT of the ipsilateral hind paw by approximately 85% seven days after lesion (time 0) compared with the mean baseline PWT (1.30 ± 0.11 g before CCI and 0.20 ± 0.02 g after CCI). The hyperalgesia produced by CCI was maintained throughout the experiment in vehicle-treated mice, but it was reversed by moclobemide (300 μmol/kg, s.c.) from 1 to 4 h after treatment ( Fig. 1B ; F(6,72) = 13.55, P b 0.001). Moclobemide also presented an antinociceptive effect at 100 μmol/kg, but not at 30 μmol/kg ( Fig. 1C ; F(6,46) = 4.87, P b 0.001), with an ID 50 value of 39 (18-84) μmol/kg and an I max value of 81 ± 10%.
The paw withdrawal threshold of sham-operated animals treated with 2-DMPI (300 μmol/kg, s.c.) was not significantly different from vehicle-treated mice ( Fig. 2A ; F(6,60) = 0.16, P = 0.987). However, the administration of 2-DMPI (300 μmol/kg, s.c.) in the CCI-submitted mice produced an antihyperalgesic effect from 1 to 6 h after treatment ( Fig. 2B ; F(6,72)= 7.36, Pb 0.001). An antinociceptive effect was also observed 2 h after treatment with 2-DMPI at 30 μmol/kg, but not at 3 μmol/kg ( Fig. 2C ; F(6,54) =3.87, P b 0.01), with values of ID 50 and I max of 11 (4-33) μmol/kg and 99±12%, respectively.
For comparative purposes, we also tested the effect of the alpha 2 -delta (α 2 -δ) ligand pregabalin in the CCI model. Pregabalin (100 μmol/kg, s.c.) caused no change in mechanical nociceptive thresholds of shamoperated animals compared with saline-treated mice ( Fig. 3A ; F(6,66) = 0.75, P = 0.609). Nevertheless, the CCI-induced hyperalgesia was reversed by pregabalin (100 μmol/kg, s.c.) from 1 to 2 h after treatment ( Fig. 3B ; F(6,72)= 5.50, P b 0.001).
Ex vivo MAO-A activity in sham-operated or CCI-submitted mice
A significant increase in MAO-A activity was observed in the lumbar spinal cord of CCI-submitted mice compared with sham-operated animals (Fig. 4) . However, CCI did not change the MAO-A activity in the cerebral cortex or the striatum (Fig. 4) .
Effect of intrathecal administration of a 5-HT 3 receptor antagonist on the antihyperalgesic effect of reversible MAO-A inhibitors
Intrathecal administration of ondansetron (10 μg/site; 90 min after subcutaneous injection of vehicle, 2-DMPI, or moclobemide), a 5-HT 3 receptor antagonist, largely reversed the antihyperalgesic effect of the reversible MAO-A inhibitors moclobemide (300 μmol/kg, s.c.; F(1,24)=13.93, Pb 0.01) and 2-DMPI (300 μmol/kg, s.c.; F(1,28)=9.62, Pb 0.01) (Fig. 5) . Furthermore, ondansetron (10 μg/site, i.t.) did not change the mechanical hyperalgesia induced by CCI in mice treated subcutaneously with vehicle (F(1,26) = 0.04, P = 0.849) (Fig. 5) . 
Effects of reversible MAO-A inhibitors and pregabalin in the rota-rod test
The motor coordination of mice was not changed by the treatment with moclobemide (300 μmol/kg, s.c.) or 2-DMPI (300 μmol/kg, s.c.) 2 h before test compared with the vehicle-treated animals, as evaluated by both the latency (s) for the first fall and the total fall number in the rota-rod test (Table 1) . Moreover, the administration of pregabalin (100 μmol/kg, s.c.) 1 h before test also caused no change in the motor coordination compared with the saline-treated animals (Table 1) .
Discussion
Neuropathic pain is triggered by lesions to the somatosensory nervous system that alter its structure and function so that pain occurs spontaneously and responses to noxious and innocuous stimuli are pathologically amplified (Costigan et al., 2009) . The treatment of neuropathic pain is challenging, in part because of its multiple etiologies, symptoms and underlying mechanisms (Bridges et al., 2001; Stacey, 2005) . Antidepressants have been successfully used for the treatment of this type of chronic pain (Sindrup et al., 2005) .
In this study, we evaluated the potential antinociceptive action of two antidepressants, the reversible MAO-A inhibitors moclobemide and 2-DMPI, in a mouse model of neuropathic pain. Both moclobemide and 2-DMPI presented a long-lasting and efficacious antinociceptive effect in CCI-submitted mice. In accordance with previous data showing that 2-DMPI exhibited a potency five-fold higher than moclobemide at inhibiting in vitro MAO-A activity (Villarinho et al., 2012a) , 2-DMPI was approximately four times more potent than moclobemide at reducing the hyperalgesia induced by CCI. Indicating the inhibition of MAO-A when administered in vivo, previous studies demonstrated that 2-DMPI and moclobemide presented antidepressantlike effect and increased central monoamine levels in doses where they possess antinociceptive effect (Da Prada et al., 1989; Miura et al., 1996; Villarinho et al., 2012a) . Moreover, we also tested the effect of pregabalin, a first line drug for the treatment of neuropathic pain (Gajraj, 2007) , in the CCI-induced hyperalgesia. Similar to reversible MAO-A inhibitors, pregabalin also exhibited an efficacious antihyperalgesic action at a dose (100 μmol/kg) that caused no change on motor coordination function. However, the antinociceptive effect of moclobemide and 2-DMPI was more long-lasting than that produced by pregabalin.
Consistent with our results, there is increasing evidence supporting the analgesic potential of MAO-A inhibitors (Apaydin et al., 2001; Bianchi et al., 1992; Coquoz et al., 1993; Dina et al., 2008; Pirildar et al., 2003; Schreiber et al., 1998) . The selective and irreversible MAO-A inhibitor clorgyline produced an antiallodynic effect in a model of alcoholic neuropathy in rats (Dina et al., 2008) . Moreover, Apaydin et al. (2001) demonstrated in a preliminary report that moclobemide attenuated mechanical hyperalgesia in rats submitted to mild sciatic nerve compression. However, the authors did not investigate the mechanism underlying this antinociceptive effect or possible changes in MAO-A activity in this neuropathic pain model.
To explore whether chronic constriction of the sciatic nerve could induce any alteration of MAO-A in specific central nervous system structures (lumbar spinal cord, striatum and cerebral cortex) implicated in pain modulation (Millan, 2002) , MAO-A activity was measured in sham-operated and CCI-submitted mice. The activity of MAO-A in the lumbar spinal cord was shown to be increased in mice subjected to CCI. To our knowledge, this is the first study showing changes in the MAO-A activity in the lumbar spinal cord of neuropathic mice, suggesting a possible involvement of this enzyme in the pathophysiological mechanisms of CCI neuropathic pain model.
Chronic constriction of the sciatic nerve could lead to a decrease in the availability of the neurotransmitter serotonin, which plays a critical role in descending pain modulation pathways (Millan, 2002) , by increasing the MAO-A activity in the lumbar spinal cord. Previous studies have demonstrated that the serotonin level is markedly decreased in some central nervous system structures involved in pain pathways, including the cerebral cortex, the ventrobasal thalamus, the raphe magnus nucleus, and the spinal cord in various neuropathic pain models (Goettl et al., 2002; Hains et al., 2002; Liu et al., 2010; Sandrini et al., 1997; Sounvoravong et al., 2004) . Furthermore, Vogel et al. (2003) showed a decrease in serotonin levels in the lumbar spinal cord of CCI-submitted mice. Because spinal levels of serotonin are important for the antinociceptive effect of many drugs (Alloui et al., 2002; Arcioni et al., 2002; Bilge et al., 2012; Kawamata et al., 2002; Kawamura et al., 1998; Pelissier et al., 1996) , 2-DMPI and moclobemide could be exerting their analgesic effect by inhibiting MAO-A activity and consequently increasing the levels of serotonin in the spinal cord.
Although descending serotonergic pathways have been implicated in both inhibitory and facilitatory modulation of spinal neuronal activity (Millan, 2002) , several studies have demonstrated that the activation of 5-HT 3 receptors in the spinal cord has an antinociceptive effect (Alhaider et al., 1991; Bardin et al., 2000; Giordano, 1991) . In the present study, mice were intrathecally injected with the 5-HT 3 receptor antagonist ondansetron to evaluate if the antinociceptive effects of the reversible MAO-A inhibitors 2-DMPI and moclobemide were mediated by the spinal serotonergic system. The antinociceptive effects of 2-DMPI and moclobemide were largely reversed by the intrathecal injection of ondansetron. In accordance with our results, Nakajima et al. (2012) demonstrated that the intrathecal treatment with ondansetron abolished the antihyperalgesic effect of the selective serotonin reuptake inhibitor paroxetine in a neuropathic pain model in rats. Moreover, ondansetron did not change the CCI-induced mechanical hyperalgesia in mice treated with vehicle. This result may be expected because ondansetron, as a pure antagonist, would only produce effect in CCI-induced hyperalgesia with 
Table 1
Effects of moclobemide (300 μmol/kg, s.c., 2 h before test), 2-DMPI (300 μmol/kg, s.c., 2 h before test) or pregabalin (100 μmol/kg, s.c., 1 h before test) treatment on latency for the first fall (s) and total number of falls in the rota-rod test in mice. an increased endogenous agonist (5-HT) tone, which probably did not occur in spinal cord of CCI-submitted mice, since MAO-A activity was augmented. Furthermore, some studies have shown that the intrathecal administration of the selective 5-HT 3 receptor agonist chlorophenylbiguanide (m-CPBG) produced antiallodynic effects in neuropathic rats, which appear to be mediated by γ-amino butyric acid (GABA)ergic inhibitory synaptic transmission (Hayashida et al., 2012; Okazaki et al., 2008) . Moreover, previous studies showed that the 5-HT 3A receptor subunit is present in GABAergic and enkephalinergic neurons (Huang et al., 2008) and that the activation of 5-HT 3 receptors evokes GABA release (Kawamata et al., 2003) in the spinal dorsal horn, suggesting that 5-HT 3 receptor activation underlies the antinociceptive effect of serotonin at the spinal cord level. Therefore, by increasing the spinal levels of serotonin, the reversible MAO-A inhibitors 2-DMPI and moclobemide could activate 5-HT 3 receptors on inhibitory interneurons in the spinal dorsal horn, which can inhibit pain by increasing the release of inhibitory transmitters. Despite our results suggest that the antinociceptive effect of reversible MAO-A inhibitors was mediated by 5-TH 3 receptors, we cannot exclude the possible involvement of other serotonergic receptors, such as 5-HT 1A , 5-HT 4 and 5-HT 7 , which may also be involved in nociceptive processing (Berrocoso et al., 2007; Brenchat et al., 2012; Jeong et al., 2004) .
Finally, the highest tested dose (300 μmol/kg) of 2-DMPI and moclobemide did not affect the paw withdrawal threshold in sham-operated mice at any time measured compared with the baseline withdrawal threshold (measured before surgery procedure), indicating that these reversible MAO-A inhibitors might be effective in neuropathic pain states, without affecting physiological protective pain. Furthermore, moclobemide and 2-DMPI, at a dose with antinociceptive effect (300 μmol/kg), caused no change on motor coordination function, eliminating a possible false positive antinociceptive effect owing to a motor impairment. In a previous study (Villarinho et al., 2012a) , 2-DMPI presented fewer adverse effects than moclobemide because the latter caused a deficit in the motor activity of mice at the highest dose tested (1000 μmol/kg). Thus, 2-DMPI may be a prototype for the development of new and safer reversible inhibitors of MAO-A with a potential therapeutic value for the treatment of neuropathic pain conditions.
Conclusion
Taken together, the results of the present study showed that 2-DMPI and moclobemide presented an antinociceptive effect in the CCI neuropathic pain model in mice, which appears to be related to the activation of spinal serotonergic 5-HT 3 receptors. Furthermore, CCI-submitted mice presented an increase in MAO-A activity in the lumbar spinal cord, suggesting a possible involvement of this enzyme in the mechanism of neuropathic pain and a potential utility for reversible MAO-A inhibitors in the development of new therapeutic approaches.
